Unraveling the Complex Relationship Triad between Lipids, Obesity, and Inflammation

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Khan, Shahida A ^a   Ali, Ashraf ^a   Khan, Sarah A ^b   Zahran, Solafa A ^a   Damanhouri, Ghazi ^a   Azhar, Esam ^a   Qadri, Ishtiaq ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Neurospectroscopy and Neuroimaging Laboratory   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CYTOKINE; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; FATTY ACID; GAMMA LINOLENIC ACID; ICOSANOID; LEUKOTRIENE; LIPID; LYSOPHOSPHATIDIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN; SPHINGOSINE 1 PHOSPHATE; THROMBOCYTE ACTIVATING FACTOR; ARACHIDONIC ACID;

ARTICLE; FAT INTAKE; GENE EXPRESSION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MODULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; MALE; METABOLISM; RAT; WISTAR RAT;

ANIMALS; ARACHIDONIC ACID; INFLAMMATION; LIPIDS; MALE; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RATS; RATS, WISTAR;

EID: 84928734718     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/502749     Document Type: Article

References (138)

1. D. Giugliano, A. Ceriello, and K. Esposito, "Theeffects of diet on inflammation: emphasis on the metabolic syndrome", Journal of the American College of Cardiology, vol. 48, no. 4, pp. 677-685, 2006.
2. C. N. Serhan, "Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution", Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 3-4, pp. 141-162, 2005.
3. J. Z. Nowak, "Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids", Postepy Higieny i Medycyny Doswiadczalnej, vol. 64, pp. 115-132, 2010.
4. R. Irannejad, J. C. Tomshine, J. R. Tomshine et al., "Conformational biosensors reveal GPCR signalling from endosomes", Nature, vol. 495, no. 7442, pp. 534-538, 2013.
5. M. P. Wymann and R. Schneiter, "Lipid signalling in disease", Nature ReviewsMolecular Cell Biology, vol. 9, no. 2, pp. 162-176, 2008.
6. Y. Cheng, W. L. Kao, B. D. Mitchell et al., "Genetic effects on postprandial variations of inflammatory markers in healthy individuals", Obesity, vol. 18, no. 7, pp. 1417-1422, 2010.
7. A. Iyer, D. P. Fairlie, J. B. Prins, B. D. Hammock, and L. Brown, "Inflammatory lipid mediators in adipocyte function and obesity", Nature Reviews Endocrinology, vol. 6, no. 2, pp. 71-82, 2010.
8. E. Titos and J. Clària, "Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation", Prostaglandins and Other LipidMediators, 2013.
9. P. C. Norris and E. A. Dennis, "Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling", Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 22, pp. 8517-8522, 2012.
10. J. M. Tishinsky, R. A. Gulli, K. L. Mullen, D. J. Dyck, and L. E. Robinson, "Fish oil prevents high-saturated fat diet-induced impairments in adiponectin and insulin response in rodent soleus muscle", American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 302, no. 5, pp. R598-R605, 2012.
11. E. Oliver, F. McGillicuddy, C. Phillips, S. Toomey, and H. M. Roche, "Postgraduate Symposium: the role of inflammation and macrophage accumulation in the development of obesityinduced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA", Proceedings of the Nutrition Society, vol. 69, no. 2, pp. 232-243, 2010.
12. D. J. Baer, J. T. Judd, B. A. Clevidence, and R. P. Tracy, "Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study", The American Journal of Clinical Nutrition, vol. 79, no. 6, pp. 969-973, 2004.
13. A. H. Lichtenstein, A. T. Erkkilä, B. Lamarche, U. S. Schwab, S. M. Jalbert, and L. M. Ausman, "Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein", Atherosclerosis, vol. 171, no. 1, pp. 97-107, 2003.
14. F. Nappo, K. Esposito, M. Cioffi et al., "Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals", Journal of the American College of Cardiology, vol. 39, no. 7, pp. 1145-1150, 2002.
15. S. N. Han, L. S. Leka, A. H. Lichtenstein, L. M. Ausman, E. J. Schaefer, and S. N. Meydani, "Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia", Journal of Lipid Research, vol. 43, no. 3, pp. 445-452, 2002.
16. M. Pirro, G. Schillaci, G. Savarese et al., "Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia", European Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 6, pp. 497-502, 2004.
17. L. S. Rallidis, G. Paschos, G. K. Liakos, A. H. Velissaridou, G. Anastasiadis, and A. Zampelas, "Dietary α-linolenic acid decreases C-reactive protein, serumamyloid A and interleukin-6 in dyslipidaemic patients", Atherosclerosis, vol. 167, no. 2, pp. 237-242, 2003.
18. G. Zhao, T. D. Etherton, K. R. Martin, S. G. West, P. J. Gillies, and P. M. Kris-Etherton, "Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women", Journal of Nutrition, vol. 134, no. 11, pp. 2991-2997, 2004.
19. W. J. E. Bemelmans, J. D. Lefrandt, E. J. M. Feskens et al., "Increased α-linolenic acid intake lowersC-reactive protein, but has no effect on markers of atherosclerosis", European Journal of Clinical Nutrition, vol. 58, no. 7, pp. 1083-1089, 2004.
20. D. C. Chan, G. F. Watts, P. H. R. Barrett, L. J. Beilin, and T. A. Mori, "Effect of atorvastatin and fish oil on plasma highsensitivityC-reactive protein concentrations in individualswith visceral obesity", Clinical Chemistry, vol. 48, no. 6, part 1, pp. 877-883, 2002.
21. S. Vega-López, N. Kaul, S. Devaraj, R. Y. Cai, B. German, and I. Jialal, "Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers", Metabolism, vol. 53, no. 2, pp. 236-240, 2004.
22. A. Jellema, J. Plat, and R. P. Mensink, "Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state", European Journal of Clinical Investigation, vol. 34, no. 11, pp. 766-773, 2004.
23. T. A. Mori, D. Q. Bao, V. Burke, I. B. Puddey, G. F. Watts, and L. J. Beilin, "Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects", American Journal of Clinical Nutrition, vol. 70, no. 5, pp. 817-825, 1999.
24. T. A. Mori, R. J. Woodman, V. Burke, I. B. Puddey, K. D. Croft, and L. J. Beilin, "Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects", Free Radical Biology & Medicine, vol. 35, no. 7, pp. 772-781, 2003.
25. A. Geelen, I. A. Brouwer, E. G. Schouten, C. Kluft, M. B. Katan, and P. L. Zock, "Intake of n-3 fatty acids fromfishdoes not lower serumconcentrations of C-reactive protein in healthy subjects", European Journal of Clinical Nutrition, vol. 58, no. 10, pp. 1440-1442, 2004.
26. I. Ciubotaru, Y. S. Lee, and R. C. Wander, "Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT", Journal of Nutritional Biochemistry, vol. 14, no. 9, pp. 513-521, 2003.
27. U. Risérus, S. Basu, S. Jovinge, G. N. Fredrikson, J. Ärnlöv, and B. Vessby, "Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance", Circulation, vol. 106, no. 15, pp. 1925-1929, 2002.
28. F. Moloney, T. Yeow, A. Mullen, J. J. Nolan, and H. M. Roche, "Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus", American Journal of Clinical Nutrition, vol. 80, no. 4, pp. 887-895, 2004.
29. A. Smedman, S. Basu, S. Jovinge, G. N. Fredrikson, and B. Vessby, "Conjugated linoleic acid increased C-reactive protein in human subjects", British Journal of Nutrition, vol. 94, no. 5, pp. 791-795, 2005.
30. K. A. Massey and A. Nicolaou, "Lipidomics of oxidized polyunsaturated fatty acids", Free Radical Biology and Medicine, vol. 59, pp. 45-55, 2013.
31. W. Wahli and L. Michalik, "PPARs at the crossroads of lipid signaling and inflammation", Trends in Endocrinology and Metabolism, vol. 23, no. 7, pp. 351-363, 2012.
32. D. Mozaffarian and J. H. Y. Wu, "Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events", Journal of the American College of Cardiology, vol. 58, no. 20, pp. 2047-2067, 2011.
33. S. Caspar-Bauguil, A. Fioroni, A. Galinier et al., "Proinflammatory phospholipid arachidonic acid/eicosapentaenoic acid ratio of dysmetabolic severely obese women", Obesity Surgery, vol. 22, no. 6, pp. 935-944, 2012.
34. M. Lagarde, N. Bernoud-Hubac, C. Calzada, E. Véricel, and M. Guichardant, "Lipidomics of essential fatty acids and oxygenatedmetabolites", Molecular Nutrition & Food Research, vol. 57, no. 8, pp. 1347-1358, 2013.
35. B. E. Tourdot, I. Ahmed, and M. Holinstat, "The emerging role of oxylipins in thrombosis and diabetes", Frontiers in Pharmacology, vol. 4, p. 176, 2014.
36. T. Chilton-Lopez, M. E. Surette, D. D. Swan, A. N. Fonteh, M. M. Johnson, and F. H. Chilton, "Metabolism of gammalinolenic acid in human neutrophils", Journal of Immunology, vol. 156, no. 8, pp. 2941-2947, 1996.
37. B. Vessby, I.-B. Gustafsson, S. Tengblad, M. Boberg, and A. Andersson, "Desaturation and elongation of fatty acids and insulin action", Annals of the New York Academy of Sciences, vol. 967, pp. 183-195, 2002.
38. U. N. Das, "A defect in the activity of.6 and.5 desaturases may be a factor predisposing to the development of insulin resistance syndrome", Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 72, no. 5, pp. 343-350, 2005.
39. C. N. Serhan, J. Z. Haeggström, and C. C. Leslie, "Lipidmediator networks in cell signaling: update and impact of cytokines", The FASEB Journal, vol. 10, no. 10, pp. 1147-1158, 1996.
40. R. M. Breyer, C. K. Bagdassarian, S. A. Myers, and M. D. Breyer, "Prostanoid receptors: subtypes and signaling", Annual Review of Pharmacology and Toxicology, vol. 41, pp. 661-690, 2001.
41. E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. Fitz Gerald, "Prostanoids in health and disease", Journal of Lipid Research, vol. 50, pp. S423-S428, 2009.
42. D. Iyú, M. Jüttner, J. R. Glenn et al., "PGE1 and PGE2 modify platelet function through different prostanoid receptors", Prostaglandins and Other Lipid Mediators, vol. 94, no. 1-2, pp. 9-16, 2011.
43. J. C. Challier, S. Basu, T. Bintein et al., "Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta", Placenta, vol. 29, no. 3, pp. 274-281, 2008.
44. K. A. Roberts, S. C. Riley, R. M. Reynolds et al., "Placental structure and inflammation in pregnancies associated with obesity", Placenta, vol. 32, no. 3, pp. 247-254, 2011.
45. J. C. Madan, J. M. Davis, W. Y. Craig et al., "Maternal obesity and markers of inflammation in pregnancy", Cytokine, vol. 47, no. 1, pp. 61-64, 2009.
46. K. Samitas, D. Chorianopoulos, S. Vittorakis et al., "Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity", Respiratory Medicine, vol. 103, no. 5, pp. 750-756, 2009.
47. L. Gagnon, L. G. Filion, C. Dubois, and M. Rola-Pleszczynski, "Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production", Agents and Actions, vol. 26, no. 1-2, pp. 141-147, 1989.
48. K. L. Weaver, P. Ivester, M. Seeds, L. D. Case, J. P. Arm, and F. H. Chilton, "Effect of dietary fatty acids on inflammatory gene expression in health humans", Journal of Biological Chemistry, vol. 284, no. 23, pp. 15400-15407, 2009.
49. H. Rodríguez-Hernández, L. E. Simental-Mendía, G. Rodríguez-Ramírez, and M. A. Reyes-Romero, "Obesity and inflammation: epidemiology, risk factors, and markers of inflammation", International Journal of Endocrinology, vol. 2013, Article ID 678159, 11 pages, 2013.
50. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., "Obesity is associated with macrophage accumulation in adipose tissue", Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796-1808, 2003.
51. P. A. Kern, G. B. Di Gregorio, T. Lu, N. Rassouli, and G. Ranganathan, "Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression", Diabetes, vol. 52, no. 7, pp. 1779-1785, 2003.
52. J. N. Patel, A. Jager, C. Schalkwijk et al., "Effects of tumour necrosis factor-α in the human forearm: blood flow and endothelin-I release", Clinical Science, vol. 103, no. 4, pp. 409-415, 2002.
53. M. Bulló, P. García-Lorda, I. Megias, and J. Salas-Salvadó, "Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression", Obesity Research, vol. 11, no. 4, pp. 525-531, 2003.
54. K. D. Rainsford, "Anti-inflammatory drugs in the 21st century", Sub-Cellular Biochemistry, vol. 42, pp. 3-27, 2007.
55. S. P. Khanapure, D. S. Garvey, D. R. Janero, and L. G. Letts, "Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers", Current Topics in Medicinal Chemistry, vol. 7, no. 3, pp. 311-340, 2007.
56. M. C. Hochberg, "What have we learned from the large outcomes trials of COX-2 selective inhibitors-Therheumatologist's perspective", Clinical and Experimental Rheumatology, vol. 19, no. 6, supplement 25, pp. S15-S22, 2001.
57. J. Meyer-Kirchrath and K. Schrör, "Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract", Current Medicinal Chemistry, vol. 7, no. 11, pp. 1121-1129, 2000.
58. M. J. Zhang and M. Spite, "Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids", Annual Review of Nutrition, vol. 32, pp. 203-227, 2012.
59. S. Hong and Y. Lu, "Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury", Frontiers in Immunology, vol. 4, article 13, 2012.
60. P. C. Calder, "Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?" British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 645-662, 2013.
61. J. D. Buckley and P. R. C. Howe, "Anti-obesity effects of longchainomega-3polyunsaturated fatty acids", Obesity reviews, vol. 10, no. 6, pp. 648-659, 2009.
62. F. Dangardt, W. Osika, Y. Chen et al., "Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents", Atherosclerosis, vol. 212, no. 2, pp. 580-585, 2010.
63. N. B. Janakiramand C. V. Rao, "Role of lipoxins and resolvins as anti-inflammatory and proresolvingmediators in colon cancer", Current Molecular Medicine, vol. 9, no. 5, pp. 565-579, 2009.
64. J. Ruzickova, M. Rossmeisl, T. Prazak et al., "Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue", Lipids, vol. 39, no. 12, pp. 1177-1185, 2004.
65. G. C. Burdge, "Metabolism of α-linolenic acid in humans", Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 75, no. 3, pp. 161-168, 2006.
66. A. M. Zivkovic, J. Yang, K. Georgi et al., "Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations", Metabolomics, vol. 8, no. 6, pp. 1102-1113, 2012.
67. K. Strassburg, A. M. L. Huijbrechts, K. A. Kortekaas et al., "Quantitative profiling of oxylipins through comprehensive LCMS/MS analysis: application in cardiac surgery", Analytical and Bioanalytical Chemistry, vol. 404, no. 5, pp. 1413-1426, 2012.
68. M. I. Aveldano and H. Sprecher, "Synthesis of hydroxy fatty acids from 4, 7, 10, 13, 16, 19-[1-14C] docosahexaenoic acid by human platelets", The Journal of Biological Chemistry, vol. 258, no. 15, pp. 9339-9343, 1983.
69. H. Y. Kim, J. W. Karanian, and N. Salem Jr., "Formation of 15-lipoxygenase product from docosahexaenoic acid (22:6w3) by human platelets", Prostaglandins, vol. 40, no. 5, pp. 539-549, 1990.
70. A. Gountopoulou, G. Leondaritis, D. Galanopoulou, and M. Mavri-Vavayanni, "TNFα is a potent inducer of platelet-activating factor synthesis in adipocytes but not in preadipocytes. Differential regulation by PI3K", Cytokine, vol. 41, no. 2, pp. 174-181, 2008.
71. F. Samad, K. D. Hester, G. Yang, Y. A. Hannun, and J. Bielawski, "Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk", Diabetes, vol. 55, no. 9, pp. 2579-2587, 2006.
72. V. Di Marzo, "Targeting the endocannabinoid system: to enhance or reduce?" Nature Reviews Drug Discovery, vol. 7, no. 5, pp. 438-455, 2008.
73. D. Jones, "End of the line for cannabinoid receptor 1 as an antiobesity target?" Nature Reviews Drug Discovery, vol. 7, no. 12, pp. 961-962, 2008.
74. T. Okada, M. Miyashita, Y. Kuromori, F. Iwata, K. Harada, and H. Hattori, "Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. e40-e41, 2006.
75. G. B. Kudolo, P. Bressler, and R. A. De Fronzo, "Plasma PAF acetylhydrolase in non-insulin dependent diabetesmellitus and obesity: effect of hyperinsulinemia and lovastatin treatment", Journal of Lipid Mediators and Cell Signalling, vol. 17, no. 2, pp. 97-113, 1997.
76. T. Shimizu, "Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation", Annual Review of Pharmacology and Toxicology, vol. 49, pp. 123-150, 2009.
77. P. Chen, E. Véricel, M. Lagarde, and M. Guichardant, "Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation", The FASEB Journal, vol. 25, no. 1, pp. 382-388, 2011.
78. H. Hsiao, R. E. Sapinoro, T. H. Thatcher et al., "A novel antiinflammatory and pro-resolving role for resolvin d1 in acute cigarette smoke-induced lung inflammation", PLoS ONE, vol. 8, no. 3, Article IDe58258, 2013.
79. C. N. Serhan, N. Chiang, and T. E. Van Dyke, "Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators", Nature Reviews Immunology, vol. 8, no. 5, pp. 349-361, 2008.
80. D. S. Im, "Omega-3 fatty acids in anti-inflammation (proresolution) and GPCRs", Progress in Lipid Research, vol. 51, no. 3, pp. 232-237, 2012.
81. E. Tjonahen, S. F. Oh, J. Siegelman et al., "Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis", Chemistry and Biology, vol. 13, no. 11, pp. 1193-1202, 2006.
82. Y. Isobe, T. Kato, and M. Arita, "Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation", Frontiers in Immunology, vol. 3, Article ID Article 270, 2012.
83. A. Ariel and C. N. Serhan, "Resolvins and protectins in the termination program of acute inflammation", Trends in Immunology, vol. 28, no. 4, pp. 176-183, 2007.
84. Y. Sun, S. F. Oh, J. Uddin et al., "Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, antiinflammatory properties, and enzymatic inactivation", Journal of Biological Chemistry, vol. 282, no. 13, pp. 9323-9334, 2007.
85. M. Dona, G. Fredman, J. M. Schwab et al., "ResolvinEl, an EPA derived mediator in whole blood, selectively counterregulates leukocytes and platelets", Blood, vol. 112, no. 3, pp. 848-855, 2008.
86. W. J. Lukiw, J. Cui, V. L. Marcheselli et al., "A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease", Journal of Clinical Investigation, vol. 115, no. 10, pp. 2774-2783, 2005.
87. B. D. Levy, P. Kohli, K. Gotlinger et al., "Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness", Journal of Immunology, vol. 178, no. 1, pp. 496-502, 2007.
88. A. Neuhofer, M. Zeyda, D. Mascher et al., "Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation", Diabetes, vol. 62, no. 6, pp. 1945-1956, 2013.
89. J. Hellmann, Y. Tang, M. Kosuri, A. Bhatnagar, and M. Spite, "Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice", The FASEB Journal, vol. 25, no. 7, pp. 2399-2407, 2011.
90. E. Titos, B. Rius, A. González-Périz et al., "Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype", Journal of Immunology, vol. 187, no. 10, pp. 5408-5418, 2011.
91. V. Bocher, I. Pineda-Torra, J. Fruchart, and B. Staels, "PPARS: transcription factors controlling lipid and lipoprotein metabolism", Annals of the New York Academy of Sciences, vol. 967, pp. 7-18, 2002.
92. S. A. Smith, "Peroxisomal proliferater-activated receptors and the regulation of lipid oxidation and adipogenesis", Biochemical Society Transactions, vol. 25, no. 4, pp. 1242-1248, 1997.
93. R. Stienstra, C. Duval, M. Müller, and S. Kersten, "PPARs, obesity, and inflammation", PPAR Research, vol. 2007, Article ID 95974, 10 pages, 2007.
94. S. Mandard, M. Müller, and S. Kersten, "Peroxisome proliferator-activated receptor α target genes", Cellular and Molecular Life Sciences, vol. 61, no. 4, pp. 393-416, 2004.
95. W. Vanden Berghe, L. Vermeulen, P. Delerive, K. De Bosscher, B. Staels, and G. Haegeman, "A paradigm for gene regulation: inflammation, NF-κB and PPAR", Advances in Experimental Medicine and Biology, vol. 544, pp. 181-196, 2003.
96. P. Delerive, K. De Bosscher, S. Besnard et al., "Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1", Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048-32054, 1999.
97. P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels, "Induction of IκBα expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-α activators", The Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703-36707, 2000.
98. P. Gervois, N. Vu-Dac, R. Kleemann et al., "Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β", The Journal of Biological Chemistry, vol. 276, no. 36, pp. 33471-33477, 2001.
99. R. Stienstra, S. Mandard, N. S. Tan et al., "The Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver", Journal of Hepatology, vol. 46, no. 5, pp. 869-877, 2007.
100. P. Gervois, R. Kleemann, A. Pilon et al., "Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferatoractivated receptor-alpha activator fenofibrate", Journal of Biological Chemistry, vol. 279, no. 16, pp. 16154-16160, 2004.
101. A. Tsuchida, T. Yamauchi, S. Takekawa et al., "Peroxisome proliferator-activated receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARα, and their combination", Diabetes, vol. 54, no. 12, pp. 3358-3370, 2005.
102. J. K. Reddy and M. S. Rao, "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation", American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G852-G858, 2006.
103. E. Teissier, A. Nohara, G. Chinetti et al., "Peroxisome proliferator-activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties", Circulation Research, vol. 95, no. 12, pp. 1174-1182, 2004.
104. M. Lehrke and M. A. Lazar, "The many faces of PPARα", Cell, vol. 123, no. 6, pp. 993-999, 2005.
105. J. Auwerx, T. A. Cock, and C. Knouff, "PPAR-gamma: a thrifty transcription factor", Nuclear Receptor Signaling, vol. 1, article e006, 2003.
106. H. Koshiyama, D. Shimono, N. Kuwamura, J. Minamikawa, and Y. Nakamura, "Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes", Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 7, pp. 3452-3456, 2001.
107. M. J. Reginato, S. L. Krakow, S. T. Bailey, and M. A. Lazar, "Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma", Journal of Biological Chemistry, vol. 273, no. 4, pp. 1855-1858, 1998.
108. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation", Nature, vol. 391, no. 6662, pp. 79-82, 1998.
109. G. Pascual, A. L. Fong, S. Ogawa et al., "A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-γ", Nature, vol. 437, no. 7059, pp. 759-763, 2005.
110. O. Gavrilova, M. Haluzik, K. Matsusue et al., "Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass", The Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268-34276, 2003.
111. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, "PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL", Cell, vol. 93, no. 2, pp. 241-252, 1998.
112. J. M. Peters, S. S. T. Lee, W. Li et al., "Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ)", Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119-5128, 2000.
113. C. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, "Transcriptional repression of atherogenic inflammation: modulation by PPARδ", Science, vol. 302, no. 5644, pp. 453-457, 2003.
114. T. C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, "PPARdelta is an APC-regulated target of nonsteroidal antiinflammatory drugs", Cell, vol. 99, no. 3, pp. 335-345, 1999.
115. T. Yamauchi, J. Kamon, H. Waki et al., "The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPAR γ) deficiency and PPAR γ agonist improve insulin resistance", Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245-41254, 2001.
116. H. Reynaert, A. Geerts, and J. Henrion, "Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones", Alimentary Pharmacology & Therapeutics, vol. 22, no. 10, pp. 897-905, 2005.
117. F. P. Mancini, A. Lanni, L. Sabatino et al., "Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats", FEBS Letters, vol. 491, no. 1-2, pp. 154-158, 2001.
118. P. C. Calder, N. Ahluwalia, F. Brouns et al., "Dietary factors and low-grade inflammation in relation to overweight and obesity", British Journal of Nutrition, vol. 106, supplement 1, pp. S78-S84, 2011.
119. D. S. Kelley, P. C. Taylor, G. J. Nelson, and B. E. Mackey, "Arachidonic acid supplementation enhances synthesis of eicosanoids without suppressing immune functions in young healthy men", Lipids, vol. 33, no. 2, pp. 125-130, 1998.
120. G. E. Caughey, E. Mantzioris, R. A. Gibson, L. G. Cleland, and M. J. James, "The effect on human tumor necrosis factor β and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil", The American Journal of Clinical Nutrition, vol. 63, no. 1, pp. 116-122, 1996.
121. N. S. Kalupahana, K. J. Claycombe, and N. Moustaid-Moussa", (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights", Advances in Nutrition, vol. 2, no. 4, pp. 304-316, 2011.
122. E. M. Hjerkinn, I. Seljeflot, I. Ellingsen et al., "Influence of longterm intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia", The American Journal of Clinical Nutrition, vol. 81, no. 3, pp. 583-589, 2005.
123. J. Ruzickova, M. Rossmeisl, T. Prazak et al., "Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue", Lipids, vol. 39, no. 12, Article ID L9552, pp. 1177-1185, 2004.
124. N. S. Kalupahana, K. Claycombe, S. J. Newman et al., "Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation", Journal of Nutrition, vol. 140, no. 11, pp. 1915-1922, 2010.
125. P. Pérez-Matute, N. Pérez-Echarri, J. A. Martínez, A. Marti, and M. J. Moreno-Aliaga, "Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: rrole of apoptosis, adiponectinand tumour necrosis factor-α", The British Journal of Nutrition, vol. 97, no. 2, pp. 389-398, 2007.
126. F. Iannone and G. Lapadula, "Obesity and inflammation-targets for OA therapy", Current Drug Targets, vol. 11, no. 5, pp. 586-598, 2010.
127. M. S. Kaplan, N. Huguet, J. T. Newsom, B. H. McFarland, and J. Lindsay, "Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey", Journals of Gerontology A: Biological Sciences and Medical Sciences, vol. 58, no. 11, pp. 1018-1030, 2003.
128. L. A. Adams, J. F. Lymp, J. St. Sauver et al., "The natural history of nonalcoholic fatty liver disease: a population-based cohort study", Gastroenterology, vol. 129, no. 1, pp. 113-121, 2005.
129. P. Angulo, "Medical progress: nonalcoholic fatty liver disease", The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
130. E. Park, E. Bae, J. Yi et al., "Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles", Environmental Toxicology and Pharmacology, vol. 30, no. 2, pp. 162-168, 2010.
131. L. Vona-Davis and D. P. Rose, "The obesity-inflammationeicosanoid axis in breast cancer", Journal of Mammary Gland Biology and Neoplasia, vol. 18, no. 3-4, pp. 291-307, 2013.
132. J. Clària, "Resolution of acute inflammation and the role of lipid mediators", The Scientific World Journal, vol. 10, pp. 1553-1555, 2010.
133. P. C. Calder, "n-3 polyunsaturated fatty acids and inflammation: From molecular biology to the clinic", Lipids, vol. 38, no. 4, pp. 343-352, 2003.
134. P. C. Calder, "n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases", The American Journal of Clinical Nutrition, vol. 83, no. 6, supplement, pp. 1505S-1519S, 2006.
135. G. Riccardi, R. Giacco, and A. A. Rivellese, "Dietary fat, insulin sensitivity and themetabolic syndrome", Clinical Nutrition, vol. 23, no. 4, pp. 447-456, 2004.
136. U. N. Das, "Is obesity an inflammatory condition?" Nutrition, vol. 17, no. 11-12, pp. 953-966, 2001.
137. H. Liu, Y. Qiu, Y. Mu et al., "A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats", Nutrition Research, vol. 33, no. 10, pp. 849-858, 2013.
138. J. P. Thaler and M. W. Schwartz, "Minireview: inflammation and obesity pathogenesis: the hypothalamus heats up", Endocrinology, vol. 151, no. 9, pp. 4109-4115, 2010.